

Haesuk Park, Ph.D Curriculum Vitae

Office Address

University of Florida
College of Pharmacy
Department of Pharmaceutical Outcomes & Policy
1225 Center Drive HPNP 3325
Gainesville, FL 32611
(352) 273-6261 (office)
(352) 273-6270 (fax)
Email: hpark@cop.ufl.edu

EDUCATION

- Fall 08 – May 13 **The University of Texas at Austin**, Austin, Texas
Doctor of Philosophy, Pharmacy
- Sep 00 – Aug 02 **Chung-Ang University**, Seoul, South Korea
Master of Pharmacy, Pharmaceutics
- Sep 96 – Aug 00 **Chung-Ang University**, Seoul, South Korea
Bachelor of Pharmacy

EMPLOYMENT

- Jul 19 - Present **University of Florida College of Pharmacy**, Gainesville, Florida
Associate Professor (tenured)
- Aug 13 – Jun 19 **University of Florida College of Pharmacy**, Gainesville, Florida
Assistant Professor
- Sep 09 – May 13 **The University of Texas at Austin College of Pharmacy**, Austin, Texas
Graduate Research Assistant
- Jun 11 – Aug 11 **Shire Pharmaceuticals**, Wayne, Pennsylvania
Summer Internship
- Jun 10 – Aug 10 **Xcenda**, Palm Harbor, Florida
Summer Internship
- Sep 08 – Aug 09 **The University of Texas at Austin**, Austin, Texas
Teaching Assistant
- Oct 03 – Jun 08 **DreamPharma Corp. (Hanwha)**, Seoul, South Korea
Manager, Business Development & Licensing
- Sep 00 – Jun 02 **Myung-Sung Pharmacy**, Seoul, South Korea
Part-time Staff Pharmacist
- Sep 00 – Aug 02 **Chung-Ang University**, Seoul, South Korea
Graduate Research Assistant

GRANTS (reverse chronological order)

Current Funding

Title: "Using machine learning to predict direct-acting antiviral treatment failure in patients with chronic hepatitis C virus infection"

Funding Source: UF Informatics Institute and UF CTSI

Role: Principal investigator (5%)

Total costs: \$60,000

Time period: April 2019 - March 2020

Title: "A behavioral economic intervention to reduce marijuana use in truant youth"

Funding: NIH/NIDA K23 (K23DA046565)

Total costs: \$843,994

Role: Collaborator (PI: Dr. Yurasek)

Time period: April 2019-March 2024

Title: "Improving medication adherence with telehealthcare MTM to change health outcomes in adolescents and young adults with asthma"

Funding Source: NIH/NHLBI R01 (1 R01 HL136945)

Role: UF PI/PD (12%) – subaward with Nemours Children's Hospital (PI: Dr. Blake)

UF total costs: \$714,513

Time period: May 2018 – March 2023

Title: "Medicaid prior authorization policies for chronic hepatitis C treatment in vulnerable populations"

Funding Source: NIH/NIDA K01 (K01DA045618)

Total costs: \$648,422

Role: Principal investigator (75%)

Time period: May 2018 – April 2023

Completed Grants

Title: "Medicaid prior authorization policies for chronic hepatitis C treatment in vulnerable populations; A pilot study"

Funding Source: UF College of Pharmacy PROSPER Research Enhancement Award

Total costs: \$39,875 (5%)

Role: Principal investigator

Time period: January 2018 - April 2019

Title: "Clinical and Health Economic Outcomes of a Digital Health Offering in a Patient Population with Cardiovascular and Metabolic Chronic Diseases"

Funding Source: Proteus Digital Health

Total costs: \$68,625 (20%)

Role: Principal investigator

Time period: January 2017 - June 2018

Title: "Effects of Medicare Dialysis Quality Incentive Program on Anemia Care"

Funding source: UF College of Pharmacy PROSPER Research Enhancement Award

Role: Principal investigator (5%)

Total costs: \$33,275

Time period: August 2016 – July 2017

Title: "Quality-adjusted cost of care associated with evolution of treatment for chronic hepatitis C"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$118,863 (35%)

Time period: April 2015 - December 2016

Title: "A meta-analytic estimation of the burden of extra hepatic manifestations of HCV"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$77,100 (20%)

Time period: September 2014 - December 2015

Title: "Impact of Hepatitis C on quality-of-life: A systematic review and meta-analysis"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$35,337 (10%)

Time period: September 2014 – December 2015

Title: "Impact of a telephonic outreach program on medication adherence in Medicare beneficiaries"

Funding source: Florida Department of Health

Role: Co-PI (Research PI)

Total costs: \$92,623 (24%)

Time period: September 2014 – July 2015

Title: "Cost-effectiveness Model of Sofosbuvir/ledipasvir for Hepatitis C virus infection"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$89,950 (40%)

Time period: June 2014 – August 2015

Title: "Cost-effectiveness Model of Sofosbuvir plus peginterferon/ribavirin for Hepatitis C virus infection"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$89,950 (55%)

Time period: November 2013 – August 2014

Primary Mentor for Student Fellowship

Ghadeer Dawwas, MS, 2017-2018, American Association of University Women (AAUW) International Doctoral Degree Fellowship, \$20,000.

PUBLICATIONS (Peer reviewed original research) (reverse chronological order; underline denotes corresponding author; g denotes graduate student; p denotes postdoc fellow)

1. **Park H**, Wang W (g), Henry L, Nelson D. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. *Hepatology* 2019;69(3):1032-1045. PMID: 30289989 ***selected for editorial highlights.**

2. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal R, **Park H**. Comparative effectiveness of ticagrelor versus prasugrel for the prevention of recurrent cardiovascular diseases and adverse bleeding outcomes in patients with acute coronary syndrome. *Pharmacotherapy* 2019. [in press]
3. **Park H**, Dawwas G (g), Liu X (p), Nguyen M. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease in a large cohort of U.S. population. *Journal of Internal Medicine* 2019. doi: 10.1111/joim.12964. PMID: 31359543
4. Dawwas G (g), Brown J, Dietrich E, **Park H**. Comparative effectiveness and safety of apixaban and rivaroxaban for the prevention of recurrent venous thromboembolism and bleeding in patients with venous thromboembolism. *The Lancet Haematology* 2019;6(1): e20-28. PMID: 30558988
5. **Park H**, Liu X (p), Henry L, Harman J, Ross E. Trends in anemia care in non-dialysis dependent chronic kidney disease patients in the United States (2005-2015). *BMC Nephrology* 2018. doi:10.1186/s12882-018-1119-7. PMID: 30413150
6. Song HJ (p), **Park H**, Park S, Kwon JW. The association between proton pump inhibitor use and the risk of tuberculosis: a case-control study. *Pharmacoepidemiology and Drug Safety* 2019. doi: 10.1002/pds.4773. PMID: 30413150
7. Song HJ (p), **Park H**, Seo HJ. The association between proton pump inhibitor use and risk for tuberculosis: A systematic review. *International Journal of Tuberculosis and Lung Disease* 2019. [in press]
8. Dawwas G (g), Smith S, **Park H**. Cardiovascular outcomes of sodium glucose cotransporter-2 in patients with Type 2 diabetes. *Diabetes, Obesity and Metabolism* 2019;21(1):28-36. PMID: 30039524
9. Nguyen A, **Park H**, Nguyen P, Sheen E, Kim Y, Nguyen M. Rising inpatient encounters and economic burden for patients with non-alcoholic fatty liver disease in the United States. *Digestive Diseases and Sciences* 2019;64(3):698-707. PMID: 30327963
10. Dawwas G (g), Smith S, **Park H**. Risk of heart failure hospitalization among users of Dipeptidyl Peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonist. *Cardiovascular Diabetology* 2018. doi: 10.1186/s12933-018-0746-4. PMID: 30016946
11. Zou B, Yeo Y, Jeong D, Sheen E, **Park H**, Nguyen P, Hsu Y, Garcia G, Nguyen M. Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness. *Scientific Report* 2018;9969: doi:10.1038/s41598-018-28317-w. PMID:29967363
12. Dave C (g), Winterstein A, **Park H**, Cook R, Hartzema A. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. *Journal of Affective Disorders* 2018;238:542-546. PMID: 29936394
13. **Park H**, Jeong D, Nguyen P, Henry L, Hoang J, Kim Y, Sheen E, Nguyen M. Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. *PlosOne* 2018;13(4): e0196452: doi.org/10.1371/journal.pone.0196452. PMID: 30566488

14. Xinyi J (g), Xiao H, Segal R, Mobley W, **Park H**. Trends in readmission rates, hospital charges and mortality for patients with chronic obstructive pulmonary disease (COPD) in Florida from 2009 to 2014. *Clinical Therapeutics* 2018;40(4): 613-626. PMID: 29609879
15. **Park H**, Chen C (g), Wang W (g), Henry L, Cook R, Nelson D. Hepatitis C virus infection increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. *Hepatology* 2018;67(2):492-504. PMID: 28873225
***selected for editorial highlights.**
16. Younossi Z, **Park H**, Dieterich D, Saab S, Ahmed A, Gordon S. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all oral regimens good value to society? *Liver International* 2017;37(5):662-668.
17. **Park H**, Adeyemi A (p), Wang W (g), Roane T. Impact of a telephonic outreach program on medication adherence in Medicare Prescription Drug (MAPD) Plan beneficiaries in Florida. *Journal of the American Pharmacist Association (JAPHA)* 2017;57(1):62-66.
18. Younossi Z, **Park H**, Dieterich D, Saab S, Ahmed A, Gordon S. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The Quality-adjusted cost of care. *Medicine* 2016;95(41) p e5048
doi: 10.1097/MD.0000000000005048.
19. Younossi Z, **Park H**, Ahmed A, Gordon S, Fergusong J, Dietrich D, Saab S. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. *American Journal of Managed Care* 2016;22(5): SP205-SP211.
20. Younossi Z, **Park H**, Henry L, Adeyemi A (p), Stepanova M. The extra-hepatic manifestations of hepatitis C – a meta-analysis of prevalence rates, effects on patient-reported outcomes economic burden. *Gastroenterology* 2016;150(7):1599-1608.
21. **Park H**, Adeyemi A (p), Rascati KL. Direct medical costs and utilization of Pneumonia in the United States: An analysis of 2007-2011 Medical Expenditure Panel Survey (MEPS). *Clinical Therapeutics* 2015;37(7):1466-1476.
22. **Park H**, Adeyemi A (p), Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. *Journal of Viral Hepatitis* 2015;22(11):897-905.
23. **Park H**, Rascati KL, Keith MS. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large US dialysis organizations. *Journal of Managed Care Pharmacy* 2015;21(6):507-514.
24. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. Health costs and outcomes associated with Medicare Part D cost-sharing. *Journal of Managed Care Pharmacy* 2015;21(10):956-964.
25. Younossi Z, **Park H**, Saab S, Ahmed A, Dieterich D, Gordon S. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimen in patients with chronic hepatitis C virus genotype 1 infection. *Alimentary Pharmacology & Therapeutics* 2015;41(6):544-563.

26. Saab S, Gordon S, **Park H**, Sulkowski M, Ahmed A, Younossi Z. Cost effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C genotype 1 infection. *Alimentary Pharmacology & Therapeutics* 2014;40(6):657-675.
27. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. Adherence and persistence to prescribed medication therapy among Medicare Part D beneficiaries on dialysis: Comparisons of benefit type and benefit phase. *Journal of Managed Care Pharmacy* 2014;20(8):862-876.
28. Sterling KL, Ford KH, **Park H**, McAlister AL. Scales of smoking-related self-efficacy, belief, and intention: assessing measurement invariance among intermittent and daily high school smokers. *American Journal of Health Promotion* 2014;28(5):310-315.
29. Sterling KL, Ford KH, **Park H**, Diamond P, McAlister AL. Assessing the invariance of smoking-related self-efficacy, beliefs, and intention among high school current smokers. *Substance Use and Misuse* 2013;48(7):477-483.
30. **Park H**, Park C, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 [DPP-4] inhibitors in type 2 diabetes: Meta-analysis. *Annals of Pharmacotherapy* 2012;46(11):1453-1469.
31. Tiwana S, Rascati KL, **Park H**. Cost-effectiveness of expanded newborn screening in Texas. *Value Health* 2012;15(5):613-621.
32. **Park H**, Rascati KL, Prasla K, McBayne T. Evaluation of healthcare costs and utilization patterns for patients with gout. *Clinical Therapeutics* 2012;34(3):640-652.
33. **Park H**, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R. Cost-effectiveness of lanthanum carbonate vs. sevelamer hydrochloride in patients with end-stage renal disease: A US payer perspective. *Value Health* 2011;14:1002-1009.
34. **Park H**, Yang SW, Choi YW, et al. In vitro skin penetration and pharmacodynamic evaluation of prostaglandin E1 ethyl ester, a vasoactive prodrug of prostaglandin E1, formulated into alcoholic hydrogels. *Pharmazie* 2006;61:933-937.
35. Yang S, Yong J, Lee H, Kim H, **Park H**, Choi H. External lyogel formulation of prostaglandin E1 ethyl ester. *Journal of Korean Pharmaceutical Sciences* 2004;34:107-114. [Korean]
36. Kim H, Lee S, Choi S, **Park H**, et al. Improved dissolution characteristics of ibuprofen employing self-microemulsifying drug delivery system and their bioavailability in rats. *Journal of Korean Pharmaceutical Sciences* 2002;32:27-33. [Korean]

Submitted:

37. Choi Y (g), **Park H**, Hampp C, Brumback B, Meissner C, Yan L, Roussos-Ross D, Zhu Y, Winterstein A. Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. *Pharmacoepidemiology and Drug Safety* 2019. [revision]

38. Dawwas G (g), Smith S, Dietrich E, Lo-Ciganic W, **Park H**. Comparative effectiveness and safety of apixaban compared to warfarin in patients with venous thromboembolism: A retrospective cohort analysis. *American Journal of Health-System Pharmacy* 2019. [revision]
39. Boemmel-Wegmann (g), Lo Re V, **Park H**. Treatment uptake and cost burden of hepatitis C (HCV) therapies among HCV patients with a particular focus on HIV co-infection. *Digestive Diseases and Sciences* 2019. [under review]
40. **Park H**, Jiang X (g), Song H (p), Childs-Kean L, Lo-Ciganic W, Cook R, Nelson D. Direct-acting antiviral therapy among individuals with chronic hepatitis C and substance use disorders: A cohort study. *Hepatology* 2019.
41. Zou B, Yeo Y, Jeong D, **Park H**, Sheen E, Lee D, Garcia G, Cheung R, Nguyen M. Decreasing admission rates and mortality for HCV and increasing trend for NAFLD: a nationwide study with cost analysis from 2005-2015. *Alimentary Pharmacology & Therapeutics* 2019. [under review]
42. Premraj S, Garg M (g), **Park H**, Venugopalan V. Use of a severity stratification tool to identify oritavancin candidates, prevent hospitalization, and minimize costs. *Clinical Therapeutics* 2019 [under review]
43. Song H (p), Jiang X (g), Henry L, **Park H**. The impact of proton pump inhibitor uses on liver cancer and mortality in patients with chronic liver diseases: a systematic review and meta-analysis. *European Journal of Gastroenterology & Hepatology* 2019. [under review]
44. Dawwas G (g), Dietrich E, Davis K, **Park H**. Comparative effectiveness and safety of direct acting oral anticoagulants and warfarin in patients with venous thromboembolism and active cancer. *Clinical Therapeutics* 2019 [under review]
45. Dietrich E, Desai E (g), Garg M (g), **Park H**, Smith S. Reimbursement of ambulatory blood pressure monitoring in the U.S. commercial insurance market place. *Journal of Clinical Hypertension* 2019. [under review]

The most up-to-date list of articles can be accessed in

- (a) Google Scholar: <https://tinyurl.com/hpark-google scholar>
- (b) Pubmed: <https://tinyurl.com/hpark-pubmed>

Editorials

1. **Park H**, Rascati KL. Comparing two cost-effectiveness studies of statins for the primary prevention of cardiovascular disease: Are statins cost-effective from a Korean health system perspective? *Clinical Therapeutics* 2009;31:2916-2918.

Letters

1. Dawwas G (g), Brown J, Dietrich E, **Park H**. Can apixaban prevent venous thromboembolism better than rivaroxaban? *The Lancet Haematology-D-19-0010* 2019.

Non-Peer-Reviewed

1. Kim D, **Park H**, Rascati KL. Medication Adherence with risperidone in Texas Medicaid patients with schizophrenia. *ISPOR Connections*, 2012;Jan.
2. **Park H**, Dasgupta A, Rascati KL. Current Pharmacoeconomic issues and drug reform in South Korea. *ISPOR Connections*, 2009;Aug:11.

POSTER PRESENTATIONS (peer-reviewed; reverse chronological order; underline denotes corresponding author; g denotes student; p denotes postdoc)

1. Smith S, Desai R (g), Dietrich E, **Park H**. Trends in ambulatory and home blood pressure monitoring use for confirmation of hypertension or resistant hypertension among the commercially-insured in the U.S., 2008-2017. 2019 American Heart Association. New Orleans, LA, September 5-9, 2019.
2. Garg M (g), **Park H**. Trends in inappropriate outpatient antibiotic use in the United States. ISPE 35th Annual Meeting, Philadelphia, PA, August 24-28, 2019.
3. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal R, **Park H**. Comparative effectiveness and safety of concomitant use of antiplatelets and anticoagulants in acute coronary syndrome patients with atrial fibrillation. ISPE 35th Annual Meeting, Philadelphia, PA, August 24-28, 2019.
4. Dawwas G (g), Dietrich E, **Park H**. Comparative Effectiveness and Safety of Direct Acting Oral Anticoagulants and Warfarin in Cancer Patients with Venous Thromboembolism. ISPE 35th Annual Meeting, Philadelphia, PA, August 24-28, 2019.
5. Garg M (g), **Park H**. Impact of disease severity on healthcare costs in patients with chronic hepatitis c virus infection. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
6. Chang C (g), **Park H**, Lo-Ciganic. Use of immune checkpoint inhibitors and risk of immune-related adverse events among patients with advanced melanoma: a systematic review and network meta-analysis. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
7. Chang C (g), **Park H**, Lo-Ciganic. The prevalence of sun protective behaviors across different age groups in the us population: findings from the 2015 us health interview survey. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
8. Desai RA (g), Dietrich E, Garg M, **Park H**, Smith S. Reimbursement of ambulatory blood pressure monitoring in the commercial insurance marketplace. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
9. Desai RA (g), Dietrich E, Garg M, **Park H**, Smith S. The out-of-pocket burden of ambulatory blood pressure monitoring: a united states perspective in the commercial insurance marketplace. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.

10. Jiang X (g), Wang W (g), **Park H**. All-oral direct-acting antivirals decrease liver complications in chronic hepatitis c patients with substance use disorders in the united states. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
11. Dawwas G (g), Dietrich E, **Park H**. Comparative effectiveness and safety of antiplatelets therapy in patients with type 2 diabetes and acute coronary syndrome. ISPE midyear meeting, Rome, Italy 2019.
12. **Park H**, Liu X (p), Nguyen M. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease in a large cohort of U.S. population. The American Association for the Study of Liver Disease (AASLD) of Liver Meeting, San Francisco, CA, November 9-13, 2018. Hepatology 2018;68(S1).
13. Dawwas G (g), **Park H**. Effectiveness of apixaban versus warfarin for the prevention of cardiovascular diseases and recurrent venous thromboembolism. ISPE 34th Annual Meeting, Prague, Czech. August 22nd-26th, 2018.
14. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal S, **Park H**. Comparative Effectiveness of Prasugrel versus Ticagrelor for the Prevention of Cardiovascular Diseases in Patients with Acute Coronary Syndrome. ISPE 34th Annual Meeting, Prague, Czech. August 22nd-26th, 2018.
15. Zou B, Yeo YH, Jeong D, Sheen E, **Park H**, Nguyen P, Hsu YC, Garcia G, Nguyen MH. 360-higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States. The Digestive Disease Week (DDW), Washington DC, June 2-5, 2018. Gastroenterology 2018; 154(6): S-1086.
16. Zou B, Yeo YH, Jeong D, Sheen D, **Park H**, Lee DH, Garcia G, Nguyen MH. The trends over time of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: An Analysis on the National Inpatient Sample. DDW, Washington DC, June 2-5, 2018. Gastroenterology 2018; 154(6): S-1183.
17. Zou B, Yeo YH, Jeong D, Sheen D, **Park H**, Lee DH, Garcia G, Nguyen MH. Inpatient healthcare utilization in cirrhotic patients with acute respiratory illness (ARI): an analysis on the U.S. national inpatient sample from 2005 to 2011. DDW, Washington DC, June 2-5, 2018. Gastroenterology 2018; 154(6): S-533.
18. Jiang X (g), Wang W (g), **Park H**. Uptake of all-oral direct acting antivirals in hepatitis C virus-infected patients with substance use disorder. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, Baltimore, MD, May 19-23, 2018.
19. Dawwas G (g), Dietrich E, **Park H**. Effectiveness of apixaban versus warfarin for the prevention of cardiovascular diseases and recurrent venous thromboembolism. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19-23, 2018.
20. Garg M (g), Venugopalan V, Premraj S, **Park H**. Budget impact analysis of oritavancin for the treatment of moderate-to-severe acute bacterial skin and skin infections from a US hospital perspective. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19-23, 2018.

21. **Park H**, Wang W (g). Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. The Boston the Academy of Managed Care Pharmacy (AMCP), Boston, MA, April 23-26, 2018.
22. Boemmel-Wegmann B (g), **Park H**. Initiation rates, predictors, and cost burden of hepatitis C (HCV) treatment in HCV mono- vs HCV/HIV co-infected patients in the United States. The International Society for Pharmacoepidemiology (ISPE) Mid-Year Meeting, Toronto, Canada, April 21-24, 2018.
23. Dawwas G (g), **Park H**. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glp-1 in patients with type II diabetes. ISPE Mid-Year Meeting, Toronto, Canada, April 21-24, 2018.
24. Premraj G, Garg M (g), **Park H**. Cherabuddi K, Klinker K, Borgert S, Venugopalan V. Use of a severity assessment system in evaluating management of sstis and identifying cost-minimization strategies at a large academic hospital. The 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Madrid, April 21-24, 2018.
25. Zou B, Yeo YH, Jeong D, Henry L, **Park H**, Nguyen MH. Cirrhotic patients with acute respiratory illness in the United States encounter substantial hospital charge burden. The American Association for the Study of Liver Disease (AASLD) of Liver Meeting, Washington DC, Oct 21-23, 2017. Hepatology 2017; 66: 408A-408A.
26. **Park H**, Jeong D, Nguyen P, Kim Y, Nguyen MH. Association of different types of chronic liver diseases with hepatocellular carcinoma in the United States. AASLD Liver Meeting Washington DC, Oct 21-23, 2017. Hepatology 2017; 66: 541A-542A.
27. Dave C (g), Park H., Winterstein A, Hartzema A, Longitudinal determinants of dynamic statin adherence: a retrospective cohort study. ISPOR 22nd Annual International Meeting. Boston, MA, May 20-24, 2017.
28. Dawwas G (g), **Park H**. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas in patients with type II diabetes. ISPOR 22nd Annual International meeting, Boston, MA, May 20-24, 2017.
29. Dave C (g), Park, H., Winterstein AI, Hartzema A., Performance of machine learning algorithms in predicting 30 day heart failure readmissions risk using an administrative claims database. ISPOR 22nd Annual International Meeting. Boston, MA. May 20-24, 2017.
30. Wang W (g), **Park, H**. Hepatitis C treatment in patients with hepatitis B virus/hepatitis C virus co-infection. ISPOR 22nd Annual International Meeting. Boston, MA. May 20-24, 2017. *Research Presentation Finalist Award.
31. **Park H**, Xinyue L (p), Liu W. Impact of FDA safety warnings on erythropoiesis stimulating agents prescribing among non-dialysis chronic kidney disease patients. ISPOR 22nd Annual International Meeting. Boston, MA. May 20-24, 2017.
32. Nguyen AL, Nguyen P, Jeong D, Hoang J, Sheen E, Kim YA, **Park H**, Nguyen MH. Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcohol related liver disease in the United States

- between 2005 and 2013. DDW, May 6-9, Chicago, IL, Gastroenterology 2017;152(5): S1200 – S1201.
33. **Park H**, Wang W (g), Chen C (g), Nelson DR. Chronic hepatitis C virus infection increases risk of cardiovascular disease and chronic kidney disease in the United States. AASLD Liver Meeting, Boston, Nov 11-15, 2016. Hepatology 2016; 64: 366A-487A.
 34. Wang W (g), **Park H**. Association of interferon-based therapy and cardiovascular disease in chronic hepatitis C patients in the United States. ISPOR 21st Annual International Meeting, Washington DC. May 21-25, 2016.
 35. Dawwas G (g), **Park H**. Impact of work and activity limitations attributable to arthritis on health-related quality of life in United States veterans. ISPOR 21st Annual International Meeting, Washington DC. May 21-25, 2016.
 36. **Park H**, Adeyemi A (p), Roane T. The impact of a telephonic outreach program on medication adherence in Medicare Advantage Prescription Drug Plan members. ISPOR 18th Annual European Congress, Milan, Italy, Nov 2015. Value in Health 11/2015;18(7):A611 *Awarded the 2015 ISPOR Best New Investigator presentation award.
 37. Adeyemi A (p), Roane T, **Park H**. The impact of a telephonic outreach program on medication adherence in Medicare Advantage Prescription Drug Plan members. AMCP Educational Conference, Orlando, FL, Oct 2015. *Awarded GOLD medal poster.
 38. Younossi Z, **Park H**, Dieterich D, Saab S, Aijaz A, Gordon S. Quality-adjusted cost of care for treatment naïve (TN) patients with genotype 1 (GT1) chronic hepatitis C (CH-C): an assessment of innovation cost of drug regimens versus the value of health gains to society. AASLD Liver Meeting, San Francisco, CA, Nov 2015.
 39. Younossi Z, **Park H**, Dieterich D, Saab S, Aijaz A, Gordon S. The value of cure associated with treating treatment-naïve (TN) chronic hepatitis C (CH-C) genotype 1 (GT1): are the new all oral regimens a good value to society? AASLD Liver Meeting, San Francisco, CA, Nov 2015.
 40. **Park H**, Adeyemi A (p), Stepanova M, Linda H, Younossi Z. Hepatitis C virus (HCV) related arthritis and arthralgia: the epidemiologic and economic burden in the United States. The American College of Gastroenterology (ACG), Las Vegas, NV, Oct 2015.
 41. Henry L, **Park H**, Adeyemi A (p), Stepanova M, Younossi Z. Depression and chronic hepatitis C (CHC): a common and costly association. ACG, Las Vegas, NV, Oct 2015.
 42. Wang W (g), **Park H**. Risk factors associated with hospital admissions through Emergency Department among pediatric asthma. 30th ICPE, Boston, MA, Aug 2015.
 43. **Park H**, Adeyemi A (p), Henry L, Stepanova M, Younossi Z. Association of Hepatitis C virus infection with risk of chronic kidney disease: systematic review and meta-analysis. ISPOR 19th Annual International Meeting, Philadelphia, PA, May 2015. Value in Health 2015;18(3):A223.

44. Wang W (g), **Park H**. Comparison on pediatric asthma hospital admissions through emergency department: Medicaid vs private insurance. ISPOR 19th Annual International Meeting, Philadelphia, PA, May 2015. Value in Health 2015;18(3):A171.
45. Kim YA, Raja P, DiCarlo L, Viridi N, **Park H**. An economic model of the impact of digital medicines with a mobile application in patients with comorbid hypertension, diabetes, and hypercholesterolemia. ISPOR 19th Annual International Meeting, Philadelphia, PA, May 2015. Value in Health;18(3):A40.
46. **Park H**, Aijaz A, Dieterich D, Saab S, Gordon S, Younossi Z. Projection of health outcomes comparing LDV/SOF vs. SOF+SMV – An analysis based on clinical trial vs. real-world data. DDW, Washington DC, May 2015. Gastroenterology 04/2015; 148(4): S970.
47. Younossi Z, **Park H**, Adeyemi A, Stepanova M, Henry L. Patient reported outcomes (PROs) in chronic hepatitis C (CHC): A meta-analysis of health related quality of life (HRQL) and fatigue data. DDW, Washington DC, May 2015. Gastroenterology 04/2015; 148(4): S503.
48. Younossi Z, **Park H**, Adeyemi A, Stepanova M, Henry L. A meta-analytic estimation of the burden of extra hepatic manifestations of hepatitis C. DDW, Washington DC, May 2015. Gastroenterology 04/2015; 148(4): S503.
49. Younossi Z, Stepanova M, Henry L, Nader F, **Park H**, Lam B, Pham H, Hunt S. The quality of life journey for patients with chronic hepatitis c: from interferon and ribavirin to interferon-free and ribavirin-free regimens. EASL, Vienna, Austria, April 2015. Journal of Hepatology 04/2015;62:S637.
50. Younossi Z, Stepanova M, Henry L, **Park H**, Racila A, Hunt S. Direct medical costs associated with the extrahepatic manifestations of hepatitis c infection in the United States. EASL, Vienna, Austria, April 2015. Journal of Hepatology 04/2015;62:S596.
51. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. The impact of Medicare Part D coverage on health outcomes in end-stage renal disease (ESRD) patients. The American Pharmacists Association (APhA) Annual Meeting & Exposition 2014, Orlando, FL, Mar 2014. *Awarded 2014 APhA-APRS Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences.
52. Younossi Z, Gordon S, Saab S, Ahmed A, **Park H**, Sulkowski M. Health and economic outcomes of Sofosbuvir therapy as predicted by a Markov model in the HCV/HIV co-infected population. ISPOR 18th Annual International Meeting, Montreal, Canada, Jun 2014. Value in Health 05/2014;17(3):A37. *Received post finalist award.
53. Saab S, Gordon S, **Park H**, Ahmed A, Younossi Z. A decision analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients and those without treatment options with chronic hepatitis C virus. DDW, Chicago, IL, May 2014. Gastroenterology 05/2014;146(5):S912.
54. Saab S, Gordon S, **Park H**, Aijaz A, Younossi Z. A decision analytic Markov model to evaluate the health outcomes of sofosbuvir for treatment-naïve and treatment-

- experienced patients with chronic hepatitis C virus genotype 3 infection. *EASL*, London, UK, Apr 2014. *Gastroenterology* 05/2014;146(5):S912.
55. **Park H**, Rascati KL, Keith MS. Examination of the budget impact of the bundled Medicare prospective payment system on dialysis organizations. The National Kidney Foundation (NKF) Clinical Meetings, Orlando, FL, Apr 2013.
 56. **Park H**, Rascati KL, Keith MS. Budget impact model of Medicare bundled end-stage renal disease prospective payment system: A dialysis organization perspective. The American Society of Nephrology (ASN), San Diego, CA, Nov 2012.
 57. **Park H**, Park C, Kim YA, Rascati KL. A meta-analysis of efficacy and safety of dipeptidyl-peptidase 4 [DPP4] inhibitors in type 2 diabetes. ISPOR 17th Annual International Meeting, Washington DC, Jun 2012. *Value in Health* 06/2012;15(4):A172.
 58. **Park H**, Rascati KL. Direct costs of pneumonia in the U.S.: An analysis of 2007-2008 Medical Expenditure Panel Survey (MEPS) data. ISPOR 14th European Congress, Madrid, Spain, Nov 2011.
 59. Rascati M, **Park H**, Rascati KL. Direct costs of head and neck cancer in the U.S.: An analysis of 2007-2008 Medical Expenditure Panel Survey (MEPS) data. ISPOR 14th European Congress, Madrid, Spain, Nov 2011.
 60. Rascati KL, Prasla K, **Park H**, McBayne T. Evaluation of healthcare costs for patients with gout by serum uric acid. American College of Rheumatology 75th Annual Scientific Meeting, Chicago, IL, Nov 2011.
 61. Kim D, **Park H**, Rascati K. Measures of medication adherence in orals vs. long-acting risperidone in Texas Medicaid patients with schizophrenia. ISPOR 16th Annual International Meeting, Baltimore, MD, May 2011. *Awarded 2011 ISPOR Best Poster Award.
 62. Rascati KL, **Park H**, Prasla K, McBayne T. Comparison of healthcare costs for gout patients by uric acid level. AMCP 23rd Annual meeting, Minneapolis, MN, Apr 2011.
 63. **Park H**, Kim D, Rascati KL. Comparisons of mental health-related medical care utilization and costs following the initiation of oral vs. long-acting injectable risperidone in patients with schizophrenia. ISPOR 16th Annual International Meeting, Baltimore, MD, May 2011.
 64. Kim D, **Park H**, Rascati KL. Measures of medication adherence in orals vs. long-acting risperidone in Texas Medicaid patients with schizophrenia. The Western Pharmacoeconomics Conference 2011, Seattle, WA, Mar 2011.
 65. **Park H**, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl-peptidase 4 [DPP4] inhibitors in type 2 diabetes: Meta-analysis. APhA Annual Meeting & Exposition 2011, Seattle, WA, Mar 2011. *Awarded 2011 APhA-APRS Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences.

66. Patel P, Shah M, D'Souza A, **Park H**. Economic impact of using a hand-carried ultrasound for diagnostic thoracentesis in patients with parapneumonic effusions. 40th Critical Care Congress, San Diego, CA, Jan 2011.
67. **Park H**, Rascati KL, Keith MS. Cost-effectiveness of lanthanum vs. sevelamer hydrochloride for the treatment of hyperphosphatemia in dialysis patients. ASN, Denver, CO, Nov 2010.
68. **Park H**, Rascati KL, Keith MS. The cost-effectiveness of lanthanum carbonate vs. sevelamer hydrochloride in patients with end-stage renal disease. ISPOR 13th European Congress, Prague, Czech Republic, Nov 2010.
69. **Park H**, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl-peptidase 4 [DPP4] inhibitors in type 2 diabetes: Meta-analysis. ISPOR 13th European Congress, Prague, Czech Republic, Nov 2010.
70. **Park H**, Rascati KL, Keith MS, et al. The value of lanthanum carbonate vs. sevelamer hydrochloride in end-stage renal disease patients: An economic evaluation from a US payer perspective. AMCP Educational Conference, St. Louis, MO, Oct 2010.

PODIUM PRESENTATIONS (peer-reviewed; reverse chronological order; underline denotes corresponding author; g denotes student; p denotes postdoc)

1. Wang W (g), Lo Re III V, Guo Y, Xiao H, Brown J, **Park H**. The increased risks of non-hepatic cancers among hepatitis c virus (HCV) infected patients: a population-based cohort study in the U.S. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
2. Wang W (g), Lo Re III V, Guo Y, Xiao H, Brown J, **Park H**. The clinical and economic impact of hcv treatment on non-hepatic cancers among HCV-infected patients. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
3. **Park H**, Wang W (g), Henry L, Nelson D. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. The American Association for the Study of Liver Disease (AASLD) of Liver Meeting, San Francisco, CA, November 9-13, 2018. Hepatology 2018;68(S1).
4. Dawwas G (g), **Park H**. Effectiveness of Apixaban versus Rivaroxaban for the Prevention of Cardiovascular Diseases and Recurrent Venous Thromboembolism. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Prague, Czech Republic, August 22-26.
5. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal R, **Park H**. Comparative Effectiveness of Prasugrel versus Ticagrelor for the Prevention of Cardiovascular Diseases in Patients with Acute Coronary Syndrome. 34th ICPE, Prague, Czech Republic, August 22-26, 2018.
6. Wang W (g), Lo Re III, Xiao H, Guo Y, **Park H**. Incidence of hepatocellular carcinoma and extrahepatic cancers among HCV patients in the era of direct-acting antivirals. The International Society for Pharmacoconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, Baltimore, Maryland, May 19-23, 2018.

7. Dawwas G (g), **Park H**. Cardiovascular Safety of Sodium Glucose Cotransporter-2 Inhibitors versus Sulfonylureas in Patients with Type II Diabetes Mellitus. 33rd ICPE, Montreal, Canada, August 26-30, 2017. *Pharmacoepidemiology Drug Safety* 2017;26 (S2).
8. Choi Y (g), Meissner C, **Park H**, Brumback B, Winterstein A. Determine of days since last active medical support for chronic lung disease, associated respiratory syncytial virus hospitalizations in infants. 33rd ICPE, Montreal, Canada, August 26-30, 2017. *Pharmacoepidemiology Drug Safety* 2017;26 (S2).
9. Jiang X (g), **Park H**, Xiao H, Segal R. Trends in readmission rate and hospital charge for patients with chronic obstructive pulmonary disease in Florida from 2009 to 2014. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017.
10. Choi Y (g), Meissner C, Hampp C, **Park H**, Brumback B, Winterstein A. Development of a predictive model for respiratory syncytial virus hospitalizations among infants. International Society for Pharmacoepidemiology (ISPE) Mid-Year Meeting, April 1-4, 2017, London, U.K. *Selected as one of top twelve award winning abstracts
11. **Park H**, Jeong, D, Nguyen, P, Hoang, J, Kim, Y, Sheen, E, Nguyen, M, The Increasing Burden of Hospital Charges from Viral Hepatitis in the United States. The Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2017, Shanghai, China. Feb 17, 2017.
12. Dawwas G (g), **Park H**. Changes in diabetes therapy one year before and after discharge from a heart failure hospitalization among patients with type II diabetes. 32th ICPE, Dublin, Ireland, Aug 24- 28, 2016.
13. Boemmel-Wegmann S (g), **Park H**. Influenza vaccination update among adult asthma patients in the United States. 32th ICPE, Dublin, Ireland, Aug 24- 28, 2016.
14. Chen C (g), Wang W (g), Cook RL, **Park H**. Hepatitis C virus infection increases risk of developing chronic kidney disease. 32th ICPE, Dublin, Ireland, Aug 24- 28, 2016. *Pharmacoepidemiology and Drug Safety*. 2016; 25: 470-471.
15. Dave C (g), Hartzema A, **Park H**, Winterstein A. Baseline and time-varying determinants of statin adherence. 32nd ICPE, Dublin, Ireland, Aug 24- 28, 2016.
16. Aijaz A, Dieterich D, **Park H**, Saab S, Gordon S, Younossi Z. A Cost-Effectiveness Analysis of LDV/SOF+RBV for 12 weeks vs. LDV/SOF 24 Weeks vs. SOF+SMV 24 Weeks in CHC GT1 TE Cirrhotic Patients. The Digestive Disease Week (DDW), Washington DC, May 2015.
17. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. The Impact of Medicare Part D Coverage on Medication Adherence and Health Outcomes in End-Stage Renal Disease (ESRD) Patients. The Western Pharmacoconomics Conference (WPC), Tucson, AZ, Mar 2013. *Awarded WPC Best Podium Award.
18. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. The Impact of Medicare Part D Coverage on Medication Adherence and Health Outcomes in End-

Stage Renal Disease (ESRD) Patients. ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013. Value in Health 05/2013;16(3):A10.

19. **Park H**, Rascati KL, Keith MS. Estimating the budget impact of the Medicare bundled end-stage renal disease prospective payment system from a dialysis organization perspective. The Annual Dialysis Conference (ADC), Seattle, WA, Mar 2013.
20. **Park H**, Kim D, Rascati KL. Healthcare costs associated with initiating oral vs. long-acting injectable risperidone in patients with schizophrenia. The American Pharmacists Association (APhA) Annual Meeting & Exposition 2012, New Orleans, LA, Mar 2012.
21. **Park H**, Kim D, Rascati KL. Comparisons of mental health-related medical care utilization and costs following the initiation of oral vs. long-acting injectable risperidone in patients with schizophrenia. WPC, Seattle, WA, Mar 2011.

TEACHING

University of Florida, College of Pharmacy (2013 – present)

Critical Appraisal of Pharmacoeconomic Studies (PHA5267); 3rd year PharmD students Spring semester (1 credit hour). Approximately 280 students; Course coordinator and lectured 100% (2014-2017). This 8-week course in legacy curriculum introduces students to fundamental methods of pharmacoeconomic analysis and enhance students' ability to apply knowledge of pharmacoeconomic

Principles of Pharmacoeconomics (PHA5933); 2nd year PharmD students Fall semester (1 credit hour). Approximately 250 students; Course coordinator and lectured 95% (2016-present). This 2-week course consists of 2 team-based learning sessions, 7 content modules, and online quiz to provide a number of opportunities to critique current literature and apply pharmacoeconomic principles through relevant practice exercises and team-based activities.

Introduction to Pharmaceutical Outcomes & Policy (PHA6265/6266); 1-2nd year graduate students in POP department Spring semester (3 credit hours). Approximately 5-10 students. Instructor and lectured 15% (2014-present). I have developed three research modules including an introduction to research in health policy, meta-analysis, and medication adherence. Each module summarizes the research topics, its strength and challenges, and discussed study methods and issues.

Pharmaceutical Outcomes and Policy department research Seminar (PHA6279); All graduate students in POP department. Fall and Spring semester (2 credit hours). Course coordinator (2017-2018). I coordinated seminar and introduced a writing skills component.

An Introduction to Drug Discovery and Development (PHA6935); 1st - 2nd year college of pharmacy graduate students; summer 2017 (1 credit hour). Lecturer for pharmacoeconomics.

University of Texas at Austin, College of Pharmacy (2011- 2013)

Advanced Research Methods (PHR 281M). 4-5th year graduate students (3 credit hours) Instructor for advanced pharmacoeconomics (2011 & 2013)

ADVISING and MENTORSHIP

Doctoral Students

1. Ghadeer Dawwas, BSP Pharm, MS, MBA (primary supervisor), 2013-2018.
2. Wei Wang, BSP Pharm (primary supervisor), 2013-2019.
3. Sascha van Boemmel-Wegmann, BSP Pharm, MS (primary supervisor), 2014-present, expected to complete in Dec 2019.
4. Xinyi Jiang, MS (primary supervisor), 2014-present, expected to complete in May 2020.
5. Mahek Garg, MS (primary supervisor), 2015-present, expected to complete in Fall 2020.
6. Munaza Riaz, BSP Pharm (primary supervisor), 2017-present, expected to complete in May 2022.
7. Abdullah Alalwan, PharmD (committee member), completed in Nov 2018.
8. Yoonyoung Choi, BSP Pharm, MS (committee member), completed in May 2018.
9. Chiantan Dave, PharmD (committee member), completed in July 2017.
10. Nakyung Jeon, BSP Pharm, MS (committee member), completed in May 2017.
11. Jevay Grooms (external member; Department of Economics), completed in Aug 2017.

Master Students

1. Xinyi Jiang (primary supervisor), completed in May 2017.
2. Ghadeer Dawwas (primary supervisor), completed in May 2017.
3. Sascha J van Boemmel-Wegmann (primary supervisor), completed in Oct 2018.

SCHOLARSHIPS AND AWARDS

May 19	UF POP Outstanding publication in clinical science research award
Nov 18	AASLD-EASL Masterclass, Orlando, Florida
Nov 15	Best Poster Award at the Academy Managed Care Pharmacy (AMCP) Annual Conference
Nov 15	Best New Investigator Presentation Award at the ISPOR 18 th Annual European Congress, Milan, Italy
Apr 15	Excellence Award for Assistant Professor, University of Florida
Mar 14	Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences (ESAS) at the APhA 2014 Annual Meeting, Orlando, FL
Mar 13	Best Podium Award at the Western Pharmacoeconomic Conference (WPC), Tucson, AZ
Sep 12 – May 13	The University of Texas Continuing Fellowship Award
Jun 12	1 st place for ISPOR Outstanding Student Chapter Award at the ISPOR 17 th Annual International Meeting, Washington DC
Jun 12	ISPOR Distinguished Service Award at the ISPOR 17 th Annual International Meeting, Washington DC
Sep 11 – Aug 12	The University of Texas Continuing Fellowship Award
May 11	Best Poster Award at the ISPOR 16 th Annual International Meeting, Baltimore, MD
Mar 11	Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences (ESAS) at the APhA 2011 Annual Meeting, Seattle, WA

PROFESSIONAL ORGANIZATIONS

2008 – present	International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2009 – present	International Society for Pharmacoepidemiology (ISPE)
2011 – present	American Pharmacists Association (APhA)
2015 – present	American Association for the Study of Liver Diseases (AASLD)

PROFESSIONAL SERVICE

University of Florida (2013-present)

- 2018 - present Faculty Development Committee, member
- 2016 - present Research Committee, member
- 2016 – present Graduate Education Task Force Committee, member
- 2015 – present Faculty advisor, International Society for Pharmacoeconomics and Outcomes Research UF chapter
- 2015 Search Committee for Pharmaceutical Outcomes & Policy Department Chair, *Member*
- 2014 - present Search Committee for Asst/Assoc Prof, Pharmaceutical Outcomes & Policy, *Member*
- 2014 – present Professionalism Committee, member

PEER REVIEW ACTIVITIES

- 2013 – present American Journal of Managed Care
- 2013 – present Journal of Medical Economics
- 2013 – present Clinical Therapeutics
- 2014 – present American Journal of Cardiovascular Drugs
- 2014 – present Annals of Pharmacotherapy
- 2015 – present American Journal of Kidney Disease
- 2015 – present Value in Health
- 2016 – present Digestive Diseases and Sciences
- 2016 – present BMC Infectious Diseases
- 2017 – present Scientific Reports
- 2018 – present Journal of Hepatology
- 2018 – present Diabetes, Obesity and Metabolism
- 2018 – present Research in Social & Administrative Pharmacy

PROFESSIONAL LICENSURE

- 2000 – present Registered Pharmacist in South Korea

PROFESSIONAL SKILLS

- Decision analysis and Markov modeling (TreeAge and Excel)
- Statistical programs (SAS, SPSS, STATA and M-Plus)